Opinion|Videos|August 16, 2024

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME